4 Healthcare Stock Stories for Wednesday Wellness
Isis Pharmaceuticals (NASDAQ:ISIS): Current price $14.69
Kynamro, a drug developed by Isis, was approved by the FDA Tuesday and will be marketed by Sanofi’s Genzyme division. The medication treats a rare inherited disorder that causes extremely high cholesterol levels and heart attacks by the age of 30, and it does it by the use of a long-sought tech that can shut off specific genes that cause disease. However, there might be no more than a few hundred people in the United States with the disease, so the drug is not likely to be a superstar, but still, Kynamro could be the first commercial success for the gene silencing technique, known as antisense, which some experts believe is finally set to fulfill its promise after more than two decades of research and numerous failures.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.